Cantor Fitzgerald Weighs in on 89bio FY2025 Earnings

89bio, Inc. (NASDAQ:ETNB) – Cantor Fitzgerald issued their FY2025 EPS estimates for 89bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($2.44) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $29.00 target price on the stock. The consensus estimate for 89bio’s current full-year earnings is ($3.22) per share.

A number of other equities research analysts have also commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of 89bio in a research report on Saturday, January 18th. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of 89bio in a research report on Tuesday. Finally, Raymond James upgraded 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, 89bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

89bio Stock Performance

ETNB opened at $6.75 on Thursday. The firm’s 50-day moving average price is $7.80 and its 200-day moving average price is $8.20. The company has a market cap of $716.38 million, a P/E ratio of -2.32 and a beta of 1.14. 89bio has a 52-week low of $5.99 and a 52-week high of $16.63. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.09.

Insiders Place Their Bets

In other news, insider Quoc Le-Nguyen sold 10,963 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.49, for a total transaction of $71,149.87. Following the transaction, the insider now owns 271,833 shares in the company, valued at $1,764,196.17. This trade represents a 3.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Rohan Palekar bought 5,000 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were acquired at an average price of $7.89 per share, for a total transaction of $39,450.00. Following the transaction, the chief executive officer now directly owns 471,236 shares in the company, valued at approximately $3,718,052.04. This represents a 1.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 25,000 shares of company stock worth $202,950. Corporate insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ETNB. American Century Companies Inc. raised its stake in 89bio by 219.0% in the 2nd quarter. American Century Companies Inc. now owns 63,864 shares of the company’s stock valued at $512,000 after purchasing an additional 43,842 shares during the last quarter. Renaissance Technologies LLC acquired a new position in 89bio in the 2nd quarter valued at $2,238,000. XTX Topco Ltd acquired a new position in 89bio in the 2nd quarter valued at $256,000. Squarepoint Ops LLC acquired a new position in 89bio in the 2nd quarter valued at $327,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of 89bio by 12.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,355 shares of the company’s stock worth $251,000 after acquiring an additional 3,557 shares during the last quarter.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.